343 related articles for article (PubMed ID: 32314509)
1. Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer.
Szarvas T; Csizmarik A; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Püllen L; Jurányi Z; Kocsis Z; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
BJU Int; 2021 Jan; 127(1):44-55. PubMed ID: 32314509
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy.
Szarvas T; Csizmarik A; Váradi M; Fazekas T; Hüttl A; Nyirády P; Hadaschik B; Grünwald V; Tschirdewahn S; Shariat SF; Sevcenco S; Maj-Hes A; Kramer G
Urol Oncol; 2021 May; 39(5):296.e11-296.e19. PubMed ID: 33046366
[TBL] [Abstract][Full Text] [Related]
3. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract][Full Text] [Related]
5. Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer.
von Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Bolenz C; Weiß C; Heinrich E
Prostate; 2016 May; 76(7):613-9. PubMed ID: 26779767
[TBL] [Abstract][Full Text] [Related]
6. Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.
VON Hardenberg J; Schwartz M; Werner T; Fuxius S; Müller M; Frangenheim T; Bolenz C; Weiss C; Heinrich E
Anticancer Res; 2017 Sep; 37(9):5117-5124. PubMed ID: 28870943
[TBL] [Abstract][Full Text] [Related]
7. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W
Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908
[TBL] [Abstract][Full Text] [Related]
8. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.
Becker DJ; Iyengar AD; Punekar SR; Ng J; Zaman A; Loeb S; Becker KD; Makarov D
Anticancer Res; 2019 May; 39(5):2467-2473. PubMed ID: 31092441
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin analogs and disease control in castration-resistant prostate cancer: different biological behavior? Case series and review of the literature.
D'Angelillo RM; Greco C; Fiore M; Ippolito E; Eolo Trodella L; Iurato A; Molfese E; Ramella S; Trodella L
Tumori; 2014; 100(3):249-53. PubMed ID: 25076233
[TBL] [Abstract][Full Text] [Related]
11. Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide.
Conteduca V; Burgio SL; Menna C; Carretta E; Rossi L; Bianchi E; Masini C; Amadori D; De Giorgi U
Prostate; 2014 Dec; 74(16):1691-6. PubMed ID: 25262981
[TBL] [Abstract][Full Text] [Related]
12. The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
Mahammedi H; Planchat E; Pouget M; Durando X; Curé H; Guy L; Van-Praagh I; Savareux L; Atger M; Bayet-Robert M; Gadea E; Abrial C; Thivat E; Chollet P; Eymard JC
Oncology; 2016; 90(2):69-78. PubMed ID: 26771576
[TBL] [Abstract][Full Text] [Related]
13. Chromogranin A predicts outcome in prostate cancer patients treated with abiraterone.
Burgio SL; Conteduca V; Menna C; Carretta E; Rossi L; Bianchi E; Kopf B; Fabbri F; Amadori D; De Giorgi U
Endocr Relat Cancer; 2014 Jun; 21(3):487-93. PubMed ID: 24741024
[TBL] [Abstract][Full Text] [Related]
14. Influence of abiraterone and enzalutamide on body composition in patients with metastatic castration resistant prostate cancer.
Fischer S; Clements S; McWilliam A; Green A; Descamps T; Oing C; Gillessen S
Cancer Treat Res Commun; 2020; 25():100256. PubMed ID: 33307509
[TBL] [Abstract][Full Text] [Related]
15. Serum Neuroendocrine Markers Predict Therapy Outcome of Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis.
Liu Y; Zhao S; Wang J; Zhu Z; Luo L; Li E; Tang F; Zhao Z
Urol Int; 2019; 102(4):373-384. PubMed ID: 30517936
[TBL] [Abstract][Full Text] [Related]
16. Neuroendocrine differentiation in stage D2 prostate cancers.
Kamiya N; Suzuki H; Kawamura K; Imamoto T; Naya Y; Tochigi N; Kakuta Y; Yamaguchi K; Ishikura H; Ichikawa T
Int J Urol; 2008 May; 15(5):423-8. PubMed ID: 18452460
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
Lilleby W; Paus E; Skovlund E; Fosså SD
Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
[TBL] [Abstract][Full Text] [Related]
18. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
19. The chromogranin-A (CgA) in prostate cancer.
Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
[TBL] [Abstract][Full Text] [Related]
20. Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancer.
Csizmarik A; Keresztes D; Nagy N; Bracht T; Sitek B; Witzke K; Puhr M; Tornyi I; Lázár J; Takács L; Kramer G; Sevcenco S; Maj-Hes A; Jurányi Z; Hadaschik B; Nyirády P; Szarvas T
Int J Cancer; 2022 Oct; 151(8):1405-1419. PubMed ID: 35689436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]